Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment.
about
The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in ratsFunctional Selectivity and Antidepressant Activity of Serotonin 1A Receptor LigandsAntidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal ModelsHow do antidepressants work? New perspectives for refining future treatment approaches.Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.Future directions for serotonin and antidepressants.The role of different serotonin receptor subtypes in seizure susceptibility.Depression and cardiovascular disease in women: is there a common immunological basis? A theoretical synthesis.Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000).Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.Computational and biological evidences on the serotonergic involvement of SeTACN antidepressant-like effect in mice.Galanin (1-15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system.Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions.The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram.
P2860
Q21132285-7693DB3D-F134-44B8-B692-5D206456A070Q26799334-F5311A47-4F81-4CBF-A799-9ADE4BE9E90FQ28550792-83C827A7-07F3-43E0-9CB4-DF128C9B8DA8Q33619029-0C385058-73A1-4355-B76D-A63A5D050256Q34350194-1743A824-FFF0-49D4-93BC-C8F438CCBC63Q34497909-BBA17349-0209-4E09-8D4A-661CBF198416Q36540966-24B1FE75-6C53-4CA2-BB18-8E7929C23095Q38162732-A5280D22-6F0C-4C35-B8FF-96ABE6BDA903Q38186686-72D1AB4E-84D4-4FC8-84E8-99C0B8D40D94Q38868838-C79AAA90-05ED-44B4-ABFE-F65764E5070CQ42976701-29F88063-CD1B-4271-8D3E-9C785B339257Q46106508-CE44456A-1ABB-4009-B9A2-8F0B38915506Q48065901-86D549B2-C7ED-42DD-85AE-6F2E1B928DB9Q48432408-01EE6C23-3950-4107-A32D-5E61EFA3A9D5Q50152811-51B24899-49C4-46F3-A6B8-DD4982434D75
P2860
Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Preclinical and clinical chara ...... for antidepressant treatment.
@ast
Preclinical and clinical chara ...... for antidepressant treatment.
@en
type
label
Preclinical and clinical chara ...... for antidepressant treatment.
@ast
Preclinical and clinical chara ...... for antidepressant treatment.
@en
prefLabel
Preclinical and clinical chara ...... for antidepressant treatment.
@ast
Preclinical and clinical chara ...... for antidepressant treatment.
@en
P2093
P2860
P1476
Preclinical and clinical chara ...... for antidepressant treatment.
@en
P2093
D Puigdemont
L Lladó-Pelfort
M C Scorza
M J Portella
R Pérez-Egea
P2860
P304
P356
10.1111/J.1476-5381.2011.01770.X
P407
P50
P577
2012-11-01T00:00:00Z